Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | FABP2 | P12104 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11836094 | 0.94 | KMT2A (0.52) | KMT2AMEN1PPARACYP2D6CYP1A2 | |
| SCHEMBL10426246 | 0.89 | KMT2A (0.54) | KMT2AMEN1PPARACYP2D6CYP1A2 | |
| SCHEMBL11303263 | 0.83 | KMT2A (0.58) | KMT2AMEN1PPARACYP2D6CYP1A2 | |
| SCHEMBL363513 | 0.81 | KMT2A (0.56) | KMT2AMEN1PPARACYP2D6CYP1A2 | |
| SCHEMBL7866065 | 0.80 | TSHR (0.48) | KMT2AMEN1CYP2D6MAPTTSHR | |
| SCHEMBL637766 | 0.80 | ESR1 (0.52) | CYP2D6CYP3A4TSHRHIF1ACYP2C9 | |
| SCHEMBL5172480 | 0.80 | ESR1 (0.52) | CYP2D6CYP3A4TSHRHIF1ACYP2C9 | |
| SCHEMBL284962 | 0.80 | ESR1 (0.52) | CYP2D6CYP3A4TSHRHIF1ACYP2C9 | |
| SCHEMBL30927966 | 0.80 | TSHR (0.48) | KMT2AMEN1CYP2D6MAPTTSHR | |
| SCHEMBL697244 | 0.80 | MAP4K4 (0.55) | KMT2AMEN1PPARACYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024224086-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| US-20140336208-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8815881-B2 | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2603496-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| CN-103068806-A | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds | SIENA BIOTECH SPA | 2013-04-24 | — | — | CN | disclosed |
| WO-2012019966-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120035195-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) | 2012-02-09 | — | — | US | disclosed |
| CN-1257153-C | Novel propargylether derivatives | SINGTENTA PARTICIPATION AG (CH) | 2006-05-24 | — | — | CN | disclosed |
| EP-1140799-B1 | NOVEL PROPARGYLETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| US-6469005-B1 | CONTROLLING AND PROTECTING AGAINST PHYTOPATHOGENIC MICROORGANISMS | SYNGENTA PARTICIPATIONS AG (CH) | 2002-10-22 | — | — | US | disclosed |
| CN-1336912-A | Novel propargylether derivatives | SINGTENTA PARTICIPATION AG (CH) | 2002-02-20 | — | — | CN | disclosed |
| EP-1140799-A1 | NOVEL PROPARGYLETHER DERIVATIVES | Syngenta Participations AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| US-6300499-B1 | α1-adrenergic receptor antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-10-09 | — | — | US | disclosed |
| WO-2000041998-A1 | NOVEL PROPARGYLETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336208-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | KMT2A 1384/4885MEN1 408/4885PPARA 2177/4885 |
| US-20120035195-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | KMT2A 1384/4885MEN1 408/4885PPARA 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.